RASON promotes KRASG12C-driven tumor progression and immune evasion in non-small cell lung cancer

Abstract Background KRAS is the most frequently mutated oncogene in human cancers, with KRASG12C being a prevalent driver mutation in 12–13% non-small cell lung cancer (NSCLC) cases. Despite breakthroughs in KRASG12C inhibitors such as sotorasib (AMG-510) and adagrasib (MRTX-849), clinical resistanc...

Full description

Saved in:
Bibliographic Details
Main Authors: Jianzhuang Wu, Kexin Xie, Yixuan Zhang, Weiyi Zhang, Rongjie Cheng, Yaliang Zhang, Yugui Xia, Tongyan Liu, Rong Yin, Yudong Qiu, Tao Xu, Rutian Li, Qi Sun, Chao Yan
Format: Article
Language:English
Published: BMC 2025-03-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Online Access:https://doi.org/10.1186/s13046-025-03369-9
Tags: Add Tag
No Tags, Be the first to tag this record!